Comparative analysis of compound NSC13728 as Omomyc homodimer stabilizer by molecular dynamics simulation and MM/GBSA free energy calculation
Abstract
Myc is a master transcriptional regulator that controls almost all cellular processes, whose function is dependent on dimerization with its obligate partner Max. Stabilization of Max homodimer by small molecules (such as compound NSC13728) has proven an effective way to reduce the availability of Myc-Max dimer. Omomyc, a peptide inhibitor of Myc, is able to form Omomyc homodimer, which can competitively inhibit the binding of Myc-Max to the E-box of DNA. Considering the high amino acid sequence homology between Omomyc and Max, we put forward the hypothesis that Max-Max stabilizers could stabilize the Omomyc homodimer. Hence, through molecular dynamics (MD) simulation and molecular mechanics/generalized Born surface area (MM/GBSA) free energy calculation, we discovered that the stability of Omomyc-Omomyc is remarkably higher than that of Max-Max. Moreover, after adding the compound NSC13728 into the well-defined "Site 3," the binding affinity between two Omomyc monomers can be further increased. Compound NSC13728 has stronger binding interaction to Omomyc-Omomyc than to Max-Max. "Site 3" of Omomyc is more hydrophobic than that of Max, which enlightens us that the more potent Omomyc-Omomyc stabilizers may be hydrophobic in structure.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The strategy of indirectly regulating Myc-driven transcription through Max/Max homodimer stabilization has not been widely explored.
“Despite these promising results, the strategy of indirectly regulating Myc-driven transcription through Max/Max homodimer stabilization has not been widely explored.424”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [424]
Cites
The Amber biomolecular simulation programs
Case, D. A., Cheatham, T. E., Darden, T., Gohlke, H., Luo, R., Merz, K. M., Onufriev, A., Simmerling, C., Wang, B., & Woods, R. J. (2005) · Journal of Computational Chemistry · doi:10.1002/jcc.20290 · Cited by 9,535 · see citing works
The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities
Genheden, S., & Ryde, U. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1032936 · Cited by 5,636 · see citing works
Duan, Y., Wu, C., Chowdhury, S., Lee, M. C., Xiong, G., Zhang, W., Yang, R., Cieplak, P., Luo, R., Lee, T.-S., et al. (2003) · Journal of Computational Chemistry · doi:10.1002/jcc.10349 · Cited by 4,271 · see citing works
Onufriev, A., Bashford, D., & Case, D. A. (2004) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.20033 · Cited by 2,507 · see citing works
Approximate atomic surfaces from linear combinations of pairwise overlaps (LCPO)
Weiser, J., Shenkin, P. S., & Still, W. C. (1999) · Journal of Computational Chemistry · doi:10.1002/(sici)1096-987x(19990130)20:2 · Cited by 1,209 · see citing works
Transcriptional regulation and transformation by Myc proteins
Adhikary, S., & Eilers, M. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1703 · Cited by 1,122 · see citing works
Targeting oncogenic Myc as a strategy for cancer treatment
Chen, H., Liu, H., & Qing, G. (2018) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-018-0008-7 · Cited by 806 · see citing works
Bretones, G., Delgado, M. D., & León, J. (2015) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.03.013 · Cited by 747 · see citing works
Recognition by Max of its cognate DNA through a dimeric b/HLH/Z domain
Ferré-D’Amaré, A. R., Prendergast, G. C., Ziff, E. B., & Burley, S. K. (1993) · Nature · doi:10.1038/363038a0 · Cited by 719 · see citing works
X-Ray Structures of Myc-Max and Mad-Max Recognizing DNA
Nair, S. K., & Burley, S. K. (2003) · Cell · doi:10.1016/s0092-8674(02)01284-9 · Cited by 551 · see citing works
MYC Deregulation in Primary Human Cancers
Kalkat, M., Melo, J. D., Hickman, K. A., Lourenco, C., Redel, C., Resetca, D., Tamachi, A., Tu, W. B., & Penn, L. Z. (2017) · Genes · doi:10.3390/genes8060151 · Cited by 445 · see citing works
THE MANY ROLES OF c-Myc IN APOPTOSIS
Thompson, E. B. (1998) · Annual Review of Physiology · doi:10.1146/annurev.physiol.60.1.575 · Cited by 328 · see citing works
Target gene-independent functions of MYC oncoproteins
Baluapuri, A., Wolf, E., & Eilers, M. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0215-2 · Cited by 310 · see citing works
Design and properties of a Myc derivative that efficiently homodimerizes
Soucek, L., Helmer‐Citterich, M., Sacco, A., Jucker, R., Cesareni, G., & Nasi, S. (1998) · Oncogene · doi:10.1038/sj.onc.1202199 · Cited by 224 · see citing works
MYC protein stability is negatively regulated by BRD4
Devaiah, B. N., Mu, J., Akman, B., Uppal, S., Weissman, J. D., Cheng, D., Baranello, L., Nie, Z., Levens, D., & Singer, D. S. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1919507117 · Cited by 159 · see citing works
Mission Possible: Advances in MYC Therapeutic Targeting in Cancer
Allen-Petersen, B. L., & Sears, R. C. (2019) · BioDrugs · doi:10.1007/s40259-019-00370-5 · Cited by 143 · see citing works
Blocking Myc to Treat Cancer: Reflecting on Two Decades of Omomyc
Massó-Vallés, D., & Soucek, L. (2020) · Cells · doi:10.3390/cells9040883 · Cited by 141 · see citing works
Serero, A., Giglione, C., Sardini, A., Martinez‐Sanz, J., & Meinnel, T. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m309770200 · Cited by 138 · see citing works
MYC, MYCL, and MYCN as therapeutic targets in lung cancer
Massó-Vallés, D., Beaulieu, M.-È., & Soucek, L. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1723548 · Cited by 116 · see citing works
Temperature sensitivities of extracellular enzyme V max and K m across thermal environments
Allison, S., Romero‐Olivares, A. L., Lu, Y., Taylor, J. W., & Treseder, K. K. (2018) · Global Change Biology · doi:10.1111/gcb.14045 · Cited by 105 · see citing works
Jung, L. A., Gebhardt, A., Koelmel, W., Ade, C. P., Walz, S., Kuper, J., von Eyss, B., Letschert, S., Redel, C., d'Artista, L., et al. (2017) · Oncogene · doi:10.1038/onc.2016.354 · Cited by 101 · see citing works
Dang, C. V. (1991) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(91)90009-a · Cited by 78 · see citing works
Omomyc expression in skin prevents Myc-induced papillomatosis
Soucek, L., Nasi, S., & Evan, G. I. (2004) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401443 · Cited by 77 · see citing works
c-Myc, Genome Instability, and Tumorigenesis: The Devil Is in the Details
Wade, M. R., & Wahl, G. M. (2006) · Springer eBooks · doi:10.1007/3-540-32952-8_7 · Cited by 75 · see citing works
Stabilizers of the Max Homodimer Identified in Virtual Ligand Screening Inhibit Myc Function
Jiang, H., Bower, K. E., Beuscher, A. E., Zhou, B., Bobkov, A. A., Olson, A. J., & Vogt, P. K. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.054858 · Cited by 62 · see citing works
Mongiardi, M. P., Savino, M., Bartoli, L., Beji, S., Nanni, S., Scagnoli, F., Falchetti, M. L., Favia, A., Farsetti, A., Levi, A., et al. (2015) · Scientific Reports · doi:10.1038/srep15494 · Cited by 46 · see citing works
MYC modulators in cancer: a patent review
Wang, X., Su, X., Cheng, S.-Q., Zhi-yin, S., Huang, Z., & Ou, T. (2019) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2019.1612878 · Cited by 25 · see citing works
Multiple Synthetic Routes to the Mini-Protein Omomyc and Coiled-Coil Domain Truncations
Brown, Z. Z., Mapelli, C., Farasat, I., Shoultz, A., Johnson, S. A., Orvieto, F., Santoprete, A., Bianchi, E., McCracken, A. B., Chen, K., et al. (2019) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.9b02467 · Cited by 23 · see citing works
MYC-Mediated Synthetic Lethality for Treating Tumors
Li, X., Zhang, X., Li, X., Xie, W., & Huang, S. (2015) · Current Cancer Drug Targets · doi:10.2174/1568009615666150121162921 · Cited by 19 · see citing works
Shi, S., Wang, Q., Liu, S., Qu, Z., Li, K., Geng, X., Wang, T., & Gao, J. (2021) · Chemical Physics · doi:10.1016/j.chemphys.2021.111108 · Cited by 16 · see citing works
Self-citationAn, Y.-Q., Chen, M., Chen, Q., & Gao, J. (2019) · Medicinal Chemistry Research · doi:10.1007/s00044-019-02479-2 · Cited by 15 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396 · see citing works
Geng, X., Zhang, Y., Li, S.-H., Liu, L., Yao, R., Liu, L., & Gao, J. (2022) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2022.134673 · Cited by 14 · see citing works
Self-citationChen, X., Ma, R., Wu, W., Gao, R., Shu, Y., Dong, M., Guo, M., Tang, D., Li, D., & Ji, S. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.118195 · Cited by 14 · see citing works
Tian, H., Yan, C., & Dong, J. (2024) · Frontiers in Environmental Science · doi:10.3389/fenvs.2024.1405537 · Cited by 4 · see citing works
Hu, Z., Zeng, Y., Zhang, Y., Zhang, Q., Xu, J., & Liu, L. (2023) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14403 · Cited by 4 · see citing works
The Functions and Regulatory Chemicals of Human Leucine Zipper Transcription Factors (LZ TFs)
Yang, H., Bi, S., Yu, B., Fang, P., & Wang, J. (2025) · 化学学报 · doi:10.6023/a25020042
- Authors
- Gao, J., Wang, Y., Li, K., Zhang, J., & Geng, X.
- Affiliations
- Xuzhou Medical College (CN)
- Corresponding author
- Gao, Jian
- Venue
- Journal of Molecular Modeling
- Published
- 2022-03-16
- Volume
- 28
- Issue
- 4
- Pages
- 92-92
- ISSN
- 0948-5023 (ISSN-L)
- 1610-2940
- OpenAlex
- W4220817194
- Cited by
- 6
- References
- 31
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 2 · 2022: 1
- FWCI
- 0.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Molecular Modeling (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Natural Science Foundation of Jiangsu Province (BK20201157)
- Six Talent Peaks Project in Jiangsu Province (YY-046)
- Qinglan Project of Jiangsu Province of China (Jian Gao)
- Topics
- Physical Sciences › Computer Science › Computational Theory and Mathematics › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Interaction Studies and Fluorescence Analysis
- Keywords
- Omomyc, Max, peptide inhibitors, E-box DNA binding, hydrophobic binding site, small-molecule binding affinity, transcriptional regulation
- MeSH terms
- DNA, Protein Binding, Proto-Oncogene Proteins c-myc, Dimerization, Molecular Dynamics Simulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review